Nuvation Bio Prices Upsized $250M Convertible Note Offering at 35% Premium
NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (6.9× avg).
Summary
Nuvation Bio priced an upsized $250 million offering of convertible senior notes, securing substantial capital at a 35% premium to its stock price, which will be used for debt repayment and general corporate needs.
Key Events · Financing and Capital Events · NUVB
-
Upsized Offering Finalized
Nuvation Bio priced an upsized offering of $250 million in 0.75% Convertible Senior Notes due 2032, an increase from the previously announced $200 million offering.
-
Favorable Pricing Terms
The notes have an initial conversion price of approximately $7.84 per share, representing a 35.0% premium over the last reported stock price of $5.81 on June 25, 2026.
-
Strengthened Financial Position
Net proceeds of approximately $241.2 million will be used to pay for capped call transactions, repay existing senior secured loan obligations, and for general corporate purposes, enhancing the company's liquidity and financial flexibility.
Analysis · NUVB · Life Sciences
Nuvation Bio has finalized the terms for its upsized convertible senior notes offering, securing $250 million in capital. The notes are priced with a 35% conversion premium over the recent stock price, indicating strong investor confidence. The proceeds will be used to repay existing debt and for general corporate purposes, significantly strengthening the company's financial position and extending its operational runway.
At the time of this filing, NUVB was trading at $5.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.81 to $9.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.